Cargando…

3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?

In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose pleiotropic signaling actions profoundly impact energy metabolism. In the present review, we recapitulate the most relevant properties of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutigliano, Grazia, Bandini, Lavinia, Sestito, Simona, Chiellini, Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139928/ https://www.ncbi.nlm.nih.gov/pubmed/32183490 http://dx.doi.org/10.3390/ijms21062005

Ejemplares similares

Update on 3-iodothyronamine and its neurological and metabolic actions
por: Zucchi, Riccardo, et al.
Publicado: (2014)

Modulation of cardiac ionic homeostasis by 3-iodothyronamine
por: Ghelardoni, Sandra, et al.
Publicado: (2009)

Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3‐iodothyronamine
por: Selen Alpergin, Ebru S., et al.
Publicado: (2017)

New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection
por: Bellusci, Lorenza, et al.
Publicado: (2017)

3-Iodothyronamine Affects Thermogenic Substrates’ Mobilization in Brown Adipocytes
por: Gencarelli, Manuela, et al.
Publicado: (2020)

Thyroxine metabolite-derived 3-iodothyronamine (T1AM) and synthetic analogs as efficient suppressors of transthyretin amyloidosis
por: Kim, Bokyung, et al.
Publicado: (2023)

Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-Like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents through the Modulation of SIRT6
por: Bellusci, Lorenza, et al.
Publicado: (2020)

SUN-717 SG-2 a Novel Multi-Target Directed Ligand (MTDL) for the Treatment of Neurodegenerative Diseases (NDDS)
por: Sestito, Simona, et al.
Publicado: (2020)

ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
por: Saponaro, Federica, et al.
Publicado: (2020)

Modulation of Gene Expression by 3-Iodothyronamine: Genetic Evidence for a Lipolytic Pattern
por: Mariotti, Veronica, et al.
Publicado: (2014)

Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway
por: Rogowski, Michael, et al.
Publicado: (2019)

New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
por: Sestito, Simona, et al.
Publicado: (2018)

Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
por: Saponaro, Federica, et al.
Publicado: (2020)

Metabolic Reprogramming by 3-Iodothyronamine (T1AM): A New Perspective to Reverse Obesity through Co-Regulation of Sirtuin 4 and 6 Expression
por: Assadi-Porter, Fariba M., et al.
Publicado: (2018)

Uptake of 3‐iodothyronamine hormone analogs inhibits the growth and viability of cancer cells
por: Rogowski, Michael, et al.
Publicado: (2017)

Effect of Combined Levothyroxine (L-T(4)) and 3-Iodothyronamine (T(1)AM) Supplementation on Memory and Adult Hippocampal Neurogenesis in a Mouse Model of Hypothyroidism
por: Rutigliano, Grazia, et al.
Publicado: (2023)

Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics
por: Runfola, Massimiliano, et al.
Publicado: (2020)

Delivery of Thyronamines (TAMs) to the Brain: A Preliminary Study
por: di Leo, Nicoletta, et al.
Publicado: (2021)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Potential role of two novel agonists of thyroid hormone receptor‐β on liver regeneration
por: Perra, Andrea, et al.
Publicado: (2020)

Metabolic Reprogramming in Health and Disease
por: Chiellini, Grazia
Publicado: (2020)

T1AM/TAAR1 System Reduces Inflammatory Response and β-Amyloid Toxicity in Human Microglial HMC3 Cell Line
por: Polini, Beatrice, et al.
Publicado: (2023)

Redox Properties of 3-Iodothyronamine (T1AM) and 3-Iodothyroacetic Acid (TA1)
por: Gencarelli, Manuela, et al.
Publicado: (2022)

The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders
por: Saponaro, Federica, et al.
Publicado: (2021)

Exogenous 3-Iodothyronamine (T(1)AM) Can Affect Phosphorylation of Proteins Involved on Signal Transduction Pathways in In Vitro Models of Brain Cell Lines, but These Effects Are Not Strengthened by Its Catabolite, 3-Iodothyroacetic Acid (TA(1))
por: Bandini, Lavinia, et al.
Publicado: (2022)

Inverse Agonistic Action of 3-Iodothyronamine at the Human Trace Amine-Associated Receptor 5
por: Dinter, Juliane, et al.
Publicado: (2015)

Commentary: 3-Iodothyronamine Reduces Insulin Secretion In Vitro via a Mitochondrial Mechanism
por: Laurino, Annunziatina, et al.
Publicado: (2018)

Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases
por: Laurino, Annunziatina, et al.
Publicado: (2018)

3-Iodothyronamine Activates a Set of Membrane Proteins in Murine Hypothalamic Cell Lines
por: Bräunig, Julia, et al.
Publicado: (2018)

3-Iodothyronamine, a Novel Endogenous Modulator of Transient Receptor Potential Melastatin 8?
por: Khajavi, Noushafarin, et al.
Publicado: (2017)

Behavioral hypothermia of a domesticated lizard under treatment of the hypometabolic agent 3-iodothyronamine
por: Ha, Kyoungbong, et al.
Publicado: (2016)

Molecular Variants in Human Trace Amine-Associated Receptors and Their Implications in Mental and Metabolic Disorders
por: Rutigliano, Grazia, et al.
Publicado: (2019)

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine
por: Zhang, Xiaoqun, et al.
Publicado: (2018)

Editorial: Calcium Metabolism: Hormonal Crosstalk, Pathophysiology and Disease
por: Battafarano, Giulia, et al.
Publicado: (2022)

Voghera Sweet Pepper: A Potential Ally against Oxidative Stress and Aging
por: Gola, Federica, et al.
Publicado: (2023)

Understanding Amyloid Structures and Disease: A Continuing Challenge in Health Research
por: Chiellini, Grazia
Publicado: (2021)

Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer’s Disease?
por: Saponaro, Federica, et al.
Publicado: (2020)

Comparative Transcriptome Analysis Reveals the Potential Cardiovascular Protective Targets of the Thyroid Hormone Metabolite 3-Iodothyronamine (3-T1AM)
por: Haiyan, Zhou, et al.
Publicado: (2020)

The Trace Amine-Associated Receptor 1 Agonist 3-Iodothyronamine Induces Biased Signaling at the Serotonin 1b Receptor
por: Bräunig, Julia, et al.
Publicado: (2018)

3-iodothyronamine inhibits apoptosis induced by myocardial ischemia reperfusion via the Akt/FoxO1 signaling pathway
por: Zhou, Haiyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vj7ftp3hhejr45v9v2f3hig78m